ALLOAllogene Therapeutics, Inc.
Price
+3.7%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality strong, a flag to check, growing in the filings, the market against it.
Charts
As reported to the SEC, without any scoring.
Allogene Therapeutics, Inc. (ALLO) reported revenue of $4.6M in Q2 2026 (quarter ended Jun 30, 2026), up 480% from the same quarter a year earlier. That came with net loss of $43M. For the full year FY2025, revenue was $2.6M (+2500% year on year) and net income −$191M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 2, 2026On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of Allogene Therapeutics, Inc. (the “Company”), provided notice of his retirement from the Company in all capacities, effective November 6, 2026.Director or officer change · Form 8-K
- Aug 12, 2026Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update.Earnings release · press release
- Jun 22, 2026On June 22, 2026, the Company filed a prospectus supplement (the "Prospectus Supplement") with the Securities and Exchange Commission relating to sales of shares of its common stock having an aggregate offering price of up to $135.0 million to be sold pursuant to a certain Sales Agreement, dated November 5, 2019, as …Shareholder vote results · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.